Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by bfwon Dec 13, 2017 4:45pm
157 Views
Post# 27150910

RE:RE:RE:Denali

RE:RE:RE:Denali
jdstox wrote: regardless, I'm not going to do the thinking for this forum. I can't and won't. Do some DD. Figure things out.

You find out how far ahead of us Denali is, where it's ahead of us, and where we're ahead of them. Infer some things. Have you read their prospectus?

Post your findings insteading of asking jekyl whether we're going to 50¢. I hope he says yes.

jdstox



I finally had a chance to comb through the Denali prospectus that I delivered to the board.

Thanks for the thoughtful posts from JD and pmrider.

A few thoughts on why Denali’s market cap is so much higher than BTI:

(1) Nasdaq - They were packaged nicely and went public on the Nasdaq. BTI sits unknown on the Venture

(2) Star power - I like our new management....I really do. However, people like Marc Tessier-Levigne have followers. They will buy in to the story period.

(3) Some primate data - BTI data is derived from rodents. Denali has preliminary data about BBB penetration in non-human primates. We need to get monkey data out to the market.

(4) Clinical trails - they have candidates entering/in clinical trials. BTI needs to advance to clinical trials to get more respect from the market. We’ll need money or a partner for this but it needs to happen.

(5)Proprietary drugs - I actually don’t think this is as big of an issue. We can attach xB3 to whatever and call it a new drug.

Anyway, we have a runway forward to a much higher market cap thanks to Denali. Always good to have a comparator when you are out marketing to institutions.

bfw

Bullboard Posts